Effects of first-trimester fluoxetine exposure on the newborn
References (16)
- et al.
Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits
Fundam Appl Toxicol
(1994) - et al.
Placental transfer and fetal distribution of fluoxetine in the rat
Toxicol Appl Pharmacol
(1989) - et al.
A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats
Fundam Appl Toxicol
(1994) - et al.
In utero exposure to fluoxetine HCl increases hematoma frequency at birth
Pharmacol Biochem Behav
(1993) - et al.
The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European network of the teratology information services (ENTIS)
Reprod Toxicol
(1996) - et al.
Self-reported depression and negative pregnancy outcomes
J Clin Epidemiol
(1992) Medicaid antidepressant pregnancy exposure outcomes
Reprod Toxicol
(1994)- et al.
Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)
JAMA
(1993)
Cited by (144)
Maternal use of antidepressants during pregnancy and risks for adverse perinatal outcomes: a meta-analysis
2020, Journal of Psychosomatic ResearchCitation Excerpt :Then, the full text of 92 articles was reviewed, 38 of which were excluded. Finally, a total of 54 studies were eligible and included in the systematic review and meta-analysis (Figure 1) [5,15–67]. Of the 54 observation studies included here, 48 5, 15-61 were cohort in design and 6 62-67 were case-control.
Untreated depression during pregnancy: Short- and long-term effects in offspring. A systematic review
2017, NeuroscienceCitation Excerpt :Furthermore, prenatal depression is a specific risk factor for postpartum psychosis (Ebeid et al., 2010), the most severe form of postnatal affective disorders (Gentile, 2012). On the other hand, antenatal antidepressant exposure has also been associated with poor pregnancy outcomes (Goldstein et al., 1997; Bérard et al., 2007; Gentile, 2010a; Pedersen et al., 2010), prenatal antidepressant exposure syndrome (Gentile, 2010a), and, recently, with an increased risk of autism spectrum disorder (ASD) (Gentile, 2015a). However, several studies reviewed elsewhere (Gentile, 2008, 2010b; Galbally et al., 2013) show reassuring findings.
Bias Against the Null Hypothesis in Retrospective Registries of Gestational Drug Exposure
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :After removing all animal studies, case reports, controlled observational studies, and review articles without original data, 122 articles were reviewed in detail. Five drugs or classes of drug identified in peer-reviewed published articles fulfilled the inclusion criteria (itraconazole, fluoxetine, acyclovir, statins, and mefloquine).5,10–13 Three drugs from drug company annual reports also met the inclusion criteria (quetiapine, quadrivalent human papillomavirus vaccine, and montelukast sodium).
Drugs and Environmental Agents in Pregnancy and Lactation: Teratology, Epidemiology
2016, Obstetrics: Normal and Problem PregnanciesThe use of antidepressant medication in pregnancy
2014, Best Practice and Research: Clinical Obstetrics and GynaecologyCitation Excerpt :The best established end points of teratology are congenital malformations that may be indicative of a significantly disrupted fetal environment. The extant literature indicates that congenital malformations are not associated with prenatal exposure to TCAs or SSRIs [28–31], SSRIs alone [32–41], or atypical antidepressants [37,42,43]. A study of Danish women showed an increased risk of congenital malformations and SSRI prescription redemption; however, a significant number of congenital malformations were reported in women who discontinued SSRI use before pregnancy (4.5% for those that discontinued compared with 4.9% with early pregnancy exposure and 6.8% in mid- to late-exposure), which indicates that other factors may be involved [44].
The Serotonergic System and Bone Metabolism During Pregnancy and Lactation and the Implications of SSRI Use on the Maternal-Offspring Dyad
2023, Journal of Mammary Gland Biology and Neoplasia